GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » Gross Profit

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Gross Profit : HK$2,577 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is SciClone Pharmaceuticals (Holdings) Gross Profit?

SciClone Pharmaceuticals (Holdings)'s gross profit for the six months ended in Dec. 2023 was HK$1,270 Mil. SciClone Pharmaceuticals (Holdings)'s gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was HK$2,577 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. SciClone Pharmaceuticals (Holdings)'s gross profit for the six months ended in Dec. 2023 was HK$1,270 Mil. SciClone Pharmaceuticals (Holdings)'s Revenue for the six months ended in Dec. 2023 was HK$1,698 Mil. Therefore, SciClone Pharmaceuticals (Holdings)'s Gross Margin % for the quarter that ended in Dec. 2023 was 74.82%.

SciClone Pharmaceuticals (Holdings) had a gross margin of 74.82% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 7 years, the highest Gross Margin % of SciClone Pharmaceuticals (Holdings) was 85.06%. The lowest was 74.67%. And the median was 76.98%.


SciClone Pharmaceuticals (Holdings) Gross Profit Historical Data

The historical data trend for SciClone Pharmaceuticals (Holdings)'s Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals (Holdings) Gross Profit Chart

SciClone Pharmaceuticals (Holdings) Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial 1,463.19 1,766.84 2,366.90 2,312.14 2,577.16

SciClone Pharmaceuticals (Holdings) Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 1,086.19 1,329.43 1,045.64 1,306.76 1,270.41

Competitive Comparison of SciClone Pharmaceuticals (Holdings)'s Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, SciClone Pharmaceuticals (Holdings)'s Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SciClone Pharmaceuticals (Holdings)'s Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SciClone Pharmaceuticals (Holdings)'s Gross Profit distribution charts can be found below:

* The bar in red indicates where SciClone Pharmaceuticals (Holdings)'s Gross Profit falls into.



SciClone Pharmaceuticals (Holdings) Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

SciClone Pharmaceuticals (Holdings)'s Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=3451.544 - 874.381
=2,577

SciClone Pharmaceuticals (Holdings)'s Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=1697.854 - 427.446
=1,270

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$2,577 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

SciClone Pharmaceuticals (Holdings)'s Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=1,270 / 1697.854
=74.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


SciClone Pharmaceuticals (Holdings)  (HKSE:06600) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

SciClone Pharmaceuticals (Holdings) had a gross margin of 74.82% for the quarter that ended in Dec. 2023 => Durable competitive advantage


SciClone Pharmaceuticals (Holdings) Gross Profit Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals (Holdings)'s Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


SciClone Pharmaceuticals (Holdings) (HKSE:06600) Business Description

Traded in Other Exchanges
N/A
Address
381 Middle Huaihai Road, 22nd Floor, Central Plaza, Shanghai, CHN
SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.
Executives
Ubs Group Ag 2201 Interest of corporation controlled by you
Zhao Hong 2101 Beneficial owner
Gl Capital Management Gp Limited
Meng Liang 2201 Interest of corporation controlled by you
Ascendent Silver (cayman) Limited 2501 Other
Ascendent Capital Partners Ii Gp Limited 2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, Gp, L.p. 2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, L.p. 2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.
Gl China Opportunities Carry Gp Limited
Ocean Falcon Limited 2101 Beneficial owner
Central Huijin Investment Ltd. 2201 Interest of corporation controlled by you
Bank Of China Limited 2201 Interest of corporation controlled by you
Bank Of China Group Investment Limited 2201 Interest of corporation controlled by you
Gl Capital Management Gp Ii B.c I. Ltd

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Headlines

No Headlines